HFE c282y homozygotes are at increased risk of breast and colorectal cancer

Hepatology

Volumn 51, Issue 4, 2010, Pages 1311-1318

  Osborne, Nicholas J ^a,b,c   Gurrin, Lyle C ^a,b   Allen, Katrina J ^a,c   Constantine, Clare C ^b   Delatycki, Martin B ^a,c   McLaren, Christine E ^d   Gertig, Dorota M ^b,e   Anderson, Gregory J ^f   Southey, Melissa C ^b   Olynyk, John K ^g,h,i   Powell, Lawrie W ^f,j   Hopper, John L ^b   Giles, Graham G ^b,k   English, Dallas R ^b,k  

^a MURDOCH CHILDREN'S RESEARCH INSTITUTE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c ROYAL CHILDREN'S HOSPITAL   (Australia)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e Victorian Cervical Cytology Registry Melbourne   (Australia)

^f QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^g FREMANTLE HOSPITAL   (Australia)

^h UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

ⁱ UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^j UNIVERSITY OF QUEENSLAND   (Australia)

^k CANCER EPIDEMIOLOGY CENTRE   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACID; CYSTEINE; HFE PROTEIN;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; AUSTRALIA; BREAST CANCER; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER REGISTRY; CANCER RISK; CANCER SCREENING; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; FEMALE; FOLLOW UP; GENETIC VARIABILITY; GENOTYPE; HEMOCHROMATOSIS; HETEROZYGOTE; HOMOZYGOTE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

ADULT; AGED; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; GENOTYPE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HOMOZYGOTE; HUMANS; IRON; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; RISK; TRANSFERRIN;

EID: 77950620367     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23448     Document Type: Article

References (42)

1. Ames B. Dietary carcinogens and anticarcinogens. Oxygen radicals and degenerative diseases. Science 1983;221:1256-1264.
2. PortoG, De SousaM. Iron overload and immunity. WorldJGastroenterol 2007;13:4707-4715.
3. Stevens R, Kalkwarf D. Iron, radiation, and cancer. Environ Health Per-spect 1990;87:291-300.
4. Olynyk JK, Trinder D, Ramm GA, Britton RS, Bacon BR. Hereditary hemochromatosis in the post-HFE era. HEPATOLOGY 2008;48:991-1001.
5. Gurrin LC, Osborne NJ, Constantine CC, McLaren CE, English DR, Gertig DM, et al. The natural history of serum iron indices for HFE C282Y homozygosity associated with hereditary hemochromatosis. Gas-troenterology 2008;135:1945-1952.
6. Adams PC, Barton JC. Haemochromatosis. Lancet 2007;370:1855-1860.
7. Gurrin LC, Bertalli NA, Dalton GW, Osborne NJ, Constantine CC, McLaren CE, et al. HFE C282Y/H63D compound heterozygotes are at low risk of hemochromatosis-related morbidity. HEPATOLOGY 2009;50: 94-101.
8. Altes A, Gimferrer E, Capella G, Barcelo MJ, Baiget M. Colorectal cancer and HFE gene mutations. Haematologica 1999;84:479-480.
9. Beckman LE, Van Landeghem GF, Sikstrom C, Wahlin A, Markevarn B, Hallmans G, et al. Interaction between haemochromatosis and transferrin receptor genes in different neoplastic disorders. Carcinogenesis 1999;20: 1231-1233.
10. MacDonald GA, Tarish J, Whitehall VJ, McCann SJ, Mellick GD, But-tenshaw RL, et al. No evidence of increased risk of colorectal cancer in individuals heterozygous for the Cys282Tyr haemochromatosis mutation. J Gastroenterol Hepatol 1999;14:1188-1191.
11. Shaheen NJ, Silverman LM, Keku T, Lawrence LB, Rohlfs EM, Martin CF, et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst 2003;95:154-159.
12. van der A DL, van der Hel O, Roest M, van der Schouw YT, van Gils CH, Marx JJM, et al. Heterozygosity for the Cys282Tyr mutation in the HFE gene and the risk of colorectal cancer (Netherlands). Cancer Causes Control 2003;14:541-545.
13. Chan AT, Ma J, Tranah GJ, Giovannucci EL, Rifai N, Hunter DJ, et al. Hemochromatosis gene mutations, body iron stores, dietary iron, and risk of colorectal adenoma in women. J Natl Cancer Inst 2005;97:917-926.
14. McGlynn KA, Sakoda LC, HuY, Schoen RE, Bresalier RS, Yeager M,etal. Hemochromatosis gene mutations and distal adenomatous colorectal polyps. Cancer Epidemiol Biomarkers Prev 2005;14:158-163.
15. Robinson JP, Johnson VL, Rogers PA, Houlston RS, Maher ER, Bishop DT, et al. Evidence for an association between compound heterozygosity for germ line mutations in the hemochromatosis (HFE) gene and increased risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2005;14: 1460-1463.
16. Abraham BK, Justenhoven C, Pesch B, Harth V, Weirich G, Baisch C, et al. Investigation of genetic variants of genes of the hemochromatosis pathway and their role in breast cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1102-1107.
17. Kondrashova T, Neriishi K,Ban S,Ivanova T, KrikunovaL, Shentereva N, et al. Frequency of hemochromatosis gene (HFE) mutations in Russian healthy women and patients with estrogen-dependent cancers. Biochim Biophys Acta 2006;1762:59-65.
18. Lucotte G, Dieterlen F. A European allele map of the C282Y mutation of hemochromatosis: Celtic versus Viking originof the mutation? Blood Cells Mol Dis 2003;31:262-267.
19. Hodge A, English D, McCredie M, Severi G, Boyle P, Hopper J, et al. Foods, nutrients and prostate cancer. Cancer Causes Control 2004;15:11-20.
20. MacInnis RJ, English DR, Hopper JL, Haydon AM, Gertig DM, Giles GG. Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev 2004;13:553-559.
21. Allen KJ, Gurrin LC, Constantine CC, Osborne NJ, Delatycki MB, Nicoll AJ, et al. Iron-overload-related disease in HFE hereditary hemochromato-sis. N Engl J Med 2008;358:221-230.
22. Pointon J, Wallace D, Merryweather-Clarke A, Robson K. Uncommon mutations and polymorphisms in the hemochromatosis gene. Genet Test 2000;4:151-161.
23. Zacharski LR, Chow BK, Howes PS, Shamayeva G, Baron JA, Dalman RL, et al. Decreased cancer risk after iron reduction in patients with peripheral arterial disease: results from a randomized trial. J Natl Cancer Inst 2008;100:996-1002.
24. Stevens R, Beasley R,Blumberg B. Iron-binding proteins and risk of cancer in Taiwan. J Natl Cancer Inst 1986;76:605-610.
25. Hercberg S, Estaquio C, Czernichow S, Mennen L, Noisette N, Bertrais S, et al. Iron status and risk of cancers in the SU.VI.MAX cohort. J Nutr 2005;135:2664-2668.
26. Tseng M, Greenberg ER, Sandler RS, Baron JA, Haile RW, Blumberg BS, et al. Serum ferritin concentration and recurrence of colorectal adenoma. Cancer Epidemiol Biomarkers Prev 2000;9:625-630.
27. Kato I, Dnistrian A, Schwartz M, Toniolo P, Koenig K, Shore R, et al. Iron intake, body iron stores and colorectal cancer risk in women: a nested case-control study. Int J Cancer 1999;80:693-698. (Pubitemid 29066280)
28. Cross AJ, Gunter MJ, Wood RJ, Pietinen P, Taylor PR, Virtamo J, et al. Iron and colorectal cancer risk in the alpha-tocopherol, beta-carotene cancer prevention study. Int J Cancer 2006;118:3147-3152.
29. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;75:81-84.
30. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-369.
31. Wurzelmann JI, Silver A, Schreinemachers DM, Sandler RS, Everson RB. Iron intake and the risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 1996;5:503-507.
32. Wu T, Sempos C, FreudenheimJ, Muti P, Smit E. Serum iron, copper and zinc concentrations and risk of cancer mortality in US adults. Ann Epidemiol 2004;14:195-201.
33. Selby JV, Friedman GD. Epidemiologic evidence of an association between body iron stores and risk of cancer. Int J Cancer 1988;41:677-682.
34. Knekt P, Reunanen A, Takkunen H,AromaaA, Heliovaara M, Hakuunen T. Body iron stores and risk of cancer. Int J Cancer 1994;56:379-382.
35. de Almeida SF, Carvalho IF, Cardoso CS, Cordeiro JV, Azevedo JE, Neefjes J, et al. HFE cross-talks with the MHC class I antigen presentation pathway. Blood 2005;106:971-977.
36. Porto G, Reimao R, Goncalves C, Vicente C, Justica B, de Sousa M. Haemochromatosis as a window into the study of the immunological system: a novel correlation between CD8+ lymphocytes and iron overload. Eur J Haematol 1994;52:283-290.
37. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006;131:1440-1451.
38. Santos GC, Zielenska M, Prasad M, Squire JA. Chromosome 6p amplification and cancer progression. J Clin Pathol 2007;60:1-7.
39. Diep CB, Parada LA, Teixeira MR, Eknæs M, Nesland JM, Johansson B, et al. Genetic profiling of colorectal cancer liver metastases by combined comparative genomic hybridization and G-banding analysis. Genes Chromosomes Cancer 2003;36:189-197.
40. Rhodes D, Trowsdale J. Alternate splice variants of the hemochromatosis gene HFE. Immunogenetics 1999;49:357-359.
41. Motokura T, Yi H, Kronenberg H, McBride O, Arnold A. Assignment of the human cyclin D3 gene (CCND3) to chromosome 6p\q13. Cyto-genet Cell Genet 1992;61:5-7.
42. Haydon AMM, MacInnis RJ, English DR, Morris H, Giles GG. Physical activity, insulin-like growth factor 1, insulin-like growth factor binding protein 3, and survival from colorectal cancer. Gut 2006;55:689-694.